Abstract
Tandem ASCT has been suggested as a valid approach to improve the prognosis of patients with MM and HR cytogenetic. In this observational, retrospective study, 213 patients with newly diagnosed MM and HR cytogenetic in 35 hospitals from the Spanish Myeloma Group underwent single or tandem ASCT between January 2015 and December 2019 after induction with VTD/VRD. HR cytogenetic was defined as having ≥1 of the following: del17p, t(4;14), t(14;16) or gain 1q21. More patients in the tandem group had R-ISS 3 and >1 cytogenetic abnormality at diagnosis. With a median follow-up of 31 months (range, 10–82), PFS after single ASCT was 41 months versus 48 months with tandem ASCT (p = 0.33). PFS in patients with del17p undergoing single ASCT was 41 months, while 52% of patients undergoing tandem ASCT were alive and disease free at 48 months. In conclusion, tandem ASCT partly overcomes the bad prognosis of HR cytogenetic.
Acknowledgments
We thank the following colleagues and institutions who provided assistance in the data collect for this research: Ana Serrano1, Ana López2, Carlos Aguilar3, Ma Belen Iñigo4, Dunia De Miguel5, Anna Sureda6, Alicia Roldán7, Aránzazu Garcia8, Ma Cristina Moragues9, Julio Davila10, Erik de Cabo11, Ma José Moreno12, María Casanova13, Ma Elena Ruiz14.
1Complejo Hospitalario Universitario de Albacete, Albacete, Spain; 2Hematology Department, Hospital Universitario La Paz, Madrid, Spain; 3Hematology Department, Hospital Santa Bárbara, Soria, Spain; 4Hematology Department, Hospital Clínico San Carlos, Madrid, Spain; 5Hematology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain; 6Hematology Department, Hospital Durán i Reynals (ICO l'Hospitalet), Barcelona, Spain; Hematology Department, Hospital Universitario Infanta Sofia, Madrid, Spain; 8Hematology Department, Hospital General de Segovia, Segovia, Spain; 9Hematology Department, Hospital Comarcal Francesc de Borja, Gandia, Spain; 10Hematology Department, Complejo Asistencial de Ávila, Ávila, Spain; 11Hematology Department, Hospital Universitario El Bierzo, Ponferrada, Spain; 12Hematology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; 13Hematology Department, Hospital Costa del Sol, Marbella, Spain; 14Hematology Department, Hospital Universitario del Tajo, Aranjuez, Spain.
Disclosure statement
No potential conflict of interest was reported by the author(s).